Compare HTLD & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | SPTX |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1995 | 2026 |
| Metric | HTLD | SPTX |
|---|---|---|
| Price | $11.87 | $22.29 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 605.7K | 124.9K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $805,709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | $170.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $17.59 |
| 52 Week High | $16.64 | $28.38 |
| Indicator | HTLD | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 43.19 |
| Support Level | $11.75 | $18.72 |
| Resistance Level | $12.13 | $22.75 |
| Average True Range (ATR) | 0.41 | 2.06 |
| MACD | 0.01 | -0.40 |
| Stochastic Oscillator | 21.13 | 9.60 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.